Table 3.
Baseline Characteristics of Patients According to Semaglutide Eligibility After Propensity Score-Matching Analysis
| Semaglutide-eligible (N=73) |
Semaglutide non-eligible (N=73) |
P value | Standardized mean differences |
|
|---|---|---|---|---|
| Age, years | 75 [57, 79] | 75 [59, 79] | 0.78 | 0.003 |
| Female, n (%) | 36 (49.3) | 33 (45.2) | 0.50 | 0.10 |
| Mean BMI (kg/m2) | 29.2±4.3 | 21.6±3.9 | <0.001 | 0.53 |
| Median BMI (kg/m2) | 29.2 [27.8, 31.9] | 21.5 [19.3, 24.2] | <0.001 | 0.53 |
| BMI ≥27 (kg/m2), n (%) | 73 (100) | 5 (6.9) | <0.001 | 0.52 |
| BMI ≥35 (kg/m2), n (%) | 10 (13.7) | 0 (0.0) | <0.001 | 0.56 |
| Hypertension, n (%) | 63 (86.3) | 35 (48.0) | <0.001 | 0.89 |
| Diabetes mellitus, n (%) | 47 (64.4) | 25 (34.3) | <0.001 | 0.63 |
| Dyslipidemia, n (%) | 33 (45.2) | 17 (23.3) | 0.005 | 0.47 |
| Smoker, n (%) | 27 (37.0) | 26 (35.6) | 0.91 | 0.02 |
| CKD (eGFR <60 mL/min/1.73 m2), n (%) | 53 (72.6) | 50 (68.5) | 0.59 | 0.09 |
| Atrial fibrillation, n (%) | 43 (58.9) | 43 (58.9) | 1.00 | 0.00 |
| NYHA III or IV, n (%) | 15 (20.6) | 16 (21.9) | 0.84 | 0.03 |
| History of hospitalization for HF, n (%) | 21 (28.8) | 25 (34.3) | 0.48 | 0.11 |
| Ischemic cardiomyopathy, n (%) | 19 (26.0) | 12 (16.4) | 0.15 | 0.24 |
| Stroke, n (%) | 14 (19.2) | 11 (15.1) | 0.50 | 0.11 |
| Alb (g/dL) | 3.6 [3.4, 3.9] | 3.6 [3.2, 3.9] | 0.69 | 0.04 |
| Hemoglobin (g/dL) | 13.6 [11.7, 15.4] | 12.4 [10.9, 14.3] | 0.02 | 0.13 |
| Uric acid (mg/dL) | 6.7 [5.7, 8.2] (n=68) | 6.9 [5.5. 8.1] (n=69) | 0.88 | 0.01 |
| LDL-C (mg/dL) | 95 [70, 122] (n=58) | 94 [76, 111] (n=63) | 0.88 | <0.001 |
| BNP (pg/mL) | 126.1 [59.5, 289.5] (n=61) | 221.1 [115.7, 402.2] (n=68) | 0.008 | 0.002 |
| HbA1c (%) | 6.5 [6.0, 7.2] (n=54) | 5.9 [5.5, 6.6] (n=63) | 0.001 | 0.48 |
| eGFR (mL/min/1.73 m2) | 45.6 [32.5, 64.0] | 49.0 [37.0, 65.0] | 0.24 | 0.009 |
| CRP (mg/dL) | 0.30 [0.11, 0.94] (n=73) | 0.20 [0.08, 0.60] (n=67) | 0.17 | 0.02 |
| hs-CRP (ng/mL) | 2,725 [999, 7,870] (n=48) | 1,610 [560, 3,785] (n=47) | 0.10 | <0.001 |
| LVEF (%) | 51.0 [39.0, 62.0] | 46.0 [34.9, 60.0] | 0.43 | 0.008 |
| HFrEF (LVEF <40%), n (%) | 21 (28.8) | 24 (32.9) | 0.59 | 0.09 |
| HFmrEF (40%≤LVEF<50%), n (%) | 13 (17.8) | 19 (26.0) | 0.23 | 0.20 |
| HFpEF (LVEF ≥50%), n (%) | 39 (53.4) | 30 (41.7) | 0.16 | 0.24 |
| LVDd (mm) | 52.6 [46.1, 58.6] | 51.7 [44.0, 58.2] | 0.41 | 0.12 |
| LVDs (mm) | 37.2 [30.0, 47.1] | 39.8 [29.2, 48.0] | 0.84 | 0.03 |
| Left atrial diameter (mm) | 47.0 [42.8, 51.5] | 45.2 [38.0, 48.4] | 0.06 | 0.37 |
| E/e’ (av.) | 13.8 [10.6, 16.9] (n=39) | 13.1 [10.5, 18.5] (n=60) | 0.40 | 0.03 |
| Medications | ||||
| Loop diuretic, n (%) | 58 (79.5) | 57 (78.1) | 0.84 | 0.03 |
| Thiazide, n (%) | 5 (6.9) | 2 (2.7) | 0.24 | 0.19 |
| β-blocker, n (%) | 56 (76.7) | 53 (72.6) | 0.57 | 0.09 |
| RAS inhibitor, n (%) | 63 (86.3) | 49 (67.1) | 0.006 | 0.47 |
| MRA, n (%) | 38 (52.1) | 40 (54.8) | 0.74 | 0.05 |
| SGLT2i, n (%) | 11 (15.1) | 1 (1.4) | 0.001 | 0.52 |
Values are presented as n (%), mean±standard deviation, or median [interquartile range]. Abbreviations as in Table 1.